Trial · NCT01668654
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants (Par.) With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period | Retigabine/Ezogabine TID | Any AE | 4 | Participants | |
| Number of Participants (Par.) With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period | Retigabine/Ezogabine TID | Any SAE | 0 | Participants | |
| Number of Participants With AEs Leading to Withdrawal | Retigabine/Ezogabine TID | 0 | Participants | ||
| Number of Participants With Vital Signs Outside the Pre-determined Clinically Important Findings or Outside the Normal Ranges at Any Time During the Study | Retigabine/Ezogabine TID | 0 | Participants | ||
| Number of Participants With Abnormal Clinically Significant ECG Findings Based on Investigator Judgment at Anytime During the Study | Retigabine/Ezogabine TID | 0 | Participants | ||
| Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study | Retigabine/Ezogabine TID | Stage I to Stage II | 0 | Participants | |
| Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study | Retigabine/Ezogabine TID | Stage II to Stage III | 0 | Participants | |
| Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study | Retigabine/Ezogabine TID | Stage III to Stage IV | 0 | Participants | |
| Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study | Retigabine/Ezogabine TID | Stage IV to Stage V | 2 | Participants | |
| Number of Participants With Sexual Maturation Based on the Tanner Stage I to Stage V of Puberty in Participants <=18 Years Old Throughout the Study | Retigabine/Ezogabine TID | Stage V | 2 | Participants | |
| Number of Days of Exposure to Retigabine/Ezogabine TID by Individual Participant | Retigabine/Ezogabine TID | Participant 1 | 133 | Days | |
| Number of Days of Exposure to Retigabine/Ezogabine TID by Individual Participant | Retigabine/Ezogabine TID | Participant 2 | 213 | Days | |
| Number of Days of Exposure to Retigabine/Ezogabine TID by Individual Participant | Retigabine/Ezogabine TID | Participant 3 | 196 | Days | |
| Number of Days of Exposure to Retigabine/Ezogabine TID by Individual Participant | Retigabine/Ezogabine TID | Participant 4 | 166 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01668654/results